<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no" />
    <meta name="description" content="" />
    <meta name="author" content="" />
    <title>COVAXIN Quiz</title>
    <link rel="icon" type="image/x-icon" href="assets/img/favicon.ico" />
    <!-- Font Awesome icons (free version)-->
    <script src="https://use.fontawesome.com/releases/v5.15.1/js/all.js" crossorigin="anonymous"></script>
    <!-- Google fonts-->
    <link href="https://fonts.googleapis.com/css?family=Varela+Round" rel="stylesheet" />
    <link
        href="https://fonts.googleapis.com/css?family=Nunito:200,200i,300,300i,400,400i,600,600i,700,700i,800,800i,900,900i"
        rel="stylesheet" />
    <!-- Core theme CSS (includes Bootstrap)-->
    <link href="css/styles.css" rel="stylesheet" />
</head>

<body id="page-top">
    <!-- Navigation-->
    <nav class="navbar navbar-expand-lg navbar-light fixed-top" id="mainNav">
        <div class="container">
            <a class="navbar-brand js-scroll-trigger" href="#page-top">COVAXIN Quiz</a>
            <button class="navbar-toggler navbar-toggler-right" type="button" data-toggle="collapse"
                data-target="#navbarResponsive" aria-controls="navbarResponsive" aria-expanded="false"
                aria-label="Toggle navigation">
                Menu
                <i class="fas fa-bars"></i>
            </button>
            <div class="collapse navbar-collapse" id="navbarResponsive">
                <ul class="navbar-nav ml-auto">
                    <li class="nav-item"><a class="nav-link js-scroll-trigger" href="#projects">About</a></li>
                    <li class="nav-item"><a class="nav-link js-scroll-trigger" href="#quiz">Quiz</a></li>
                    <li class="nav-item"><a class="nav-link js-scroll-trigger" href="#signup">Key Features</a></li>
                    <li class="nav-item"><a class="nav-link js-scroll-trigger" href="https://dishitasingh.github.io/Course-Code/Project-making2/mains/darkMode.html">Dark Mode</a></li>
                </ul>
            </div>
        </div>
    </nav>

    <!-- Projects-->
    <section class="projects-section bg-light" id="projects">
        <div class="container">
            <!-- Featured Project Row-->
            <div class="row align-items-center no-gutters mb-4 mb-lg-5">
                <div class="col-xl-8 col-lg-7"><img class="img-fluid mb-3 mb-lg-0"
                        src="assets/img/covaxin-1608743407-1609641081.jpg" alt="" /></div>
                <div class="col-xl-4 col-lg-5">
                    <div class="featured-text text-center text-lg-left">
                        <h4><strong>COVAXIN</strong> -Indias own Vaccine</h4>
                        <p class="text-black-50 mb-0">COVAXIN, India's indigenous COVID-19 vaccine by Bharat Biotech is
                            developed in collaboration with the Indian Council of Medical Research (ICMR) - National
                            Institute of Virology (NIV).

                            The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3
                            (Bio-Safety Level 3) high containment facility.

                            The vaccine is developed using Whole-Virion Inactivated Vero Cell derived platform
                            technology. Inactivated vaccines do not replicate and are therefore unlikely to revert and
                            cause pathological effects. They contain dead virus, incapable of infecting people but still
                            able to instruct the immune system to mount a defensive reaction against an infection.</p>
                    </div>
                </div>
            </div>
            <!-- Project One Row-->
            <div class="row justify-content-center no-gutters mb-5 mb-lg-0" id="quiz">
                <div class="col-lg-6"><img class="img-fluid" src="assets/img/photo.jpg" alt="" /></div>
                <div class="col-lg-6">
                    <div class="bg-black text-center h-100 project">
                        <div class="d-flex h-100">
                            <div class="project-text w-100 my-auto text-center text-lg-left">
                                <h4 class="text-black">Why develop Inactivated Vaccine? </h4>
                                <p class="mb-0 text-black">Conventionally, inactivated vaccines have been around for
                                    decades. Numerous vaccines for diseases such as Seasonal Influenza, Polio,
                                    Pertussis, Rabies, and Japanese Encephalitis use the same technology to develop
                                    inactivated vaccines with a safe track record of >300 million doses of supplies to
                                    date. It is the well-established, and time-tested platform in the world of vaccine
                                    technology.</p>
                                <hr class="d-none d-lg-block mb-0 ml-0" />
                            </div>
                        </div>
                    </div>
                </div>
            </div>
            <!-- Project Two Row-->
            <div class="row justify-content-center no-gutters">
                <div class="col-lg-6"><img class="img-fluid" src="assets/img/2021-02-05 (2).png" alt="" /></div>
                <div class="col-lg-6 order-lg-first">
                    <div class="bg-black text-center h-100 project">
                        <div class="d-flex h-100">
                            <div class="project-text w-100 my-auto text-center text-lg-right">
                                <h4 class="text-black">Take the Quiz </h4>
                                <p class="mb-0 text-black">Take a short quiz and know if you are fit for Indias own
                                    COVAXIN.</p>
                                <hr class="d-none d-lg-block mb-0 mr-0" />
                                <a href="https://dishitasingh.github.io/Course-Code/Project-making2/index.html"><button
                                        class="btn btn-secondary mt-4">Take the Quiz</button></a>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>
    <!-- Signup-->
    <section class="signup-section" id="signup">
        <div class="container">
            <div class="row">
                <div class="col-md-10 col-lg-8 mx-auto text-center">
                    <i class="far fa-paper-plane fa-2x mb-2 text-black"></i>
                    <h2 class="text-purple mb-5" style="color:purple; font-weight: 900;">Key Attributes:</h2>
                    <p>
                    <ul style="font-size: large; color: purple; font-weight: 1000;">

                        <li>COVAXIN is included along with immune-potentiators, also known as vaccine adjuvants, which
                            are added to the vaccine to increase and boost its immunogenicity.
                        <li>

                        <li>It is a 2-dose vaccination regimen given 28 days apart.</li>

                        <li>It is a vaccine with no sub-zero storage, no reconstitution requirement, and ready to use
                            liquid presentation in multi-dose vials, stable at 2-8oC.</li>

                        <li>Pre-clinical studies: Demonstrated strong immunogenicity and protective efficacy in animal
                            challenge studies conducted in hamsters & non-human primates. For more information about our
                            animal study, please visit our blog page on Non-Human Primates.</li>

                        <li>The vaccine received DCGI approval for Phase I & II Human Clinical Trials in July, 2020.
                        </li>

                        <li>A total of 375 subjects have been enrolled in the Phase 1 study and generated excellent
                            safety data without any reactogenicity. Vaccine-induced neutralizing antibody titers were
                            observed with two divergent SARS-CoV-2 strains. Percentage of all the side-effects combined
                            was only 15% in vaccine recipients. For further information, visit our blog page on phase 1
                            study.</li>

                        <li>In Phase 2 study, 380 participants of 12-65 years were enrolled. COVAXINTM led to tolerable
                            safety outcomes and enhanced humoral and cell-mediated immune responses. Know more about our
                            phase 2 study.</li>
                </div>
            </div>
        </div>
    </section>

    <!-- Bootstrap core JS-->
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.5.1/jquery.min.js"></script>
    <script src="https://cdn.jsdelivr.net/npm/bootstrap@4.5.3/dist/js/bootstrap.bundle.min.js"></script>
    <!-- Third party plugin JS-->
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery-easing/1.4.1/jquery.easing.min.js"></script>
    <!-- Core theme JS-->
    <script src="js/scripts.js"></script>
</body>

</html>